Rebalancing the Supply Chain: Onshoring vs. Offshoring Medical Devices After COVID-19

IDN supply-chain leaders are still recalibrating sourcing geography four years after the pandemic exposed how deeply concentrated — and fragile — global medical device manufacturing had become.

Why this matters

Picture March 2020 in a 600-bed regional health system. Surgical N95 inventories drop from a comfortable six-week buffer to a two-day supply inside a fortnight. Procurement calls the primary distributor, who calls the importer, who calls the contract manufacturer in Fujian Province — and learns that the facility is under regional lockdown. The IDN's contracts, all written around price and standardization, say nothing about geographic concentration risk or force-majeure supply continuity. The system ends up sourcing respirators through a spot broker at roughly five times the contracted unit price, with no way to verify FDA 510(k) clearance before the masks arrive.

That scenario repeated itself across virtually every product category that had drifted toward single-region offshore manufacturing over the prior two decades: ventilator subassemblies, pulse oximeter components, surgical gloves, IV fluid bags. The GAO's post-pandemic review (GAO-21-108) found that the U.S. lacked visibility into lower tiers of the medical device supply chain and had no systematic mechanism for tracking geographic concentration at the component level — a structural gap, not a bad-luck event (S1).

The policy response came quickly. Executive Order 13944 (August 2020) directed federal agencies to prioritize domestically produced essential medicines and devices. FDA expanded its shortage monitoring under 21 CFR Part 820 enforcement discretion and later proposed the Quality Management System Regulation (QMSR), aligning domestic manufacturer requirements more tightly with ISO 13485:2016 to reduce friction for reshoring (S2). But policy momentum doesn't automatically translate into better sourcing decisions for an individual IDN. The real question is: given where supply chains stand today, what combination of onshore, nearshore, and offshore sourcing actually reduces total delivered risk at an acceptable total cost?

The decisions that shape the outcome

Classifying devices by criticality and substitutability

Not all medical devices carry the same supply-chain risk. A Class III implantable device with a single qualified manufacturer is a fundamentally different sourcing problem from a Class I disposable glove with dozens of competing suppliers across multiple geographies. Before debating onshore versus offshore for any category, IDN supply-chain leaders need a clear tier map: which products, if unavailable for 30 days, would trigger patient harm or care cancellation? ECRI's supply chain resilience framework suggests stratifying items into "mission-critical," "operationally significant," and "substitutable" buckets, because the acceptable cost premium for domestic or near-shore supply is very different across those three tiers (S3).

Total cost of ownership, not unit price

The financial case for offshore sourcing has historically rested on unit-price differentials that can reach 30–50% for labor-intensive devices like disposables. But that calculation collapses when you fully load it: ocean freight, port dwell time (which spiked to 8–12 days average at major U.S. West Coast ports during 2021–2022), Section 301 tariffs on Chinese-origin goods (currently 7.5–25% across HS chapters covering many medical devices), import compliance costs, buffer-stock carrying costs, and the cost of a single stockout event. Domestic or nearshore (Mexico, Costa Rica) sourcing typically carries higher unit cost but shortens lead times from 10–16 weeks to 2–5 weeks, dramatically reducing the safety-stock investment required to maintain equivalent service levels. Precise publicly verifiable cost-comparison figures are not available for specific device categories, but IDNs running total-landed-cost models consistently find the gap narrower than the invoice price suggests.

Regulatory equivalence across geographies

An often-underestimated complexity in shifting sourcing geography is that FDA clearance status does not travel with the product when manufacturing moves. A 510(k) clearance is manufacturer-site-specific. If a domestic OEM reshores production from an offshore contract manufacturer to a U.S. facility, or if an IDN wants to qualify an alternative domestic supplier, that transition may require a new 510(k) submission or at minimum a manufacturing change notification under 21 CFR Part 807 (S2). Similarly, offshore suppliers shipping directly to U.S. facilities must hold their own FDA registration and comply with QSR/QMSR requirements. IDNs that assume "ISO 13485 certified" automatically satisfies FDA requirements are exposed: ISO 13485:2016 and FDA's QMSR overlap substantially but are not identical, particularly around complaint handling and CAPA documentation.

Dual-sourcing versus geographic diversification

Many IDNs responded to COVID by adding a second supplier — but adding a second offshore supplier in the same region solves nothing if a regional disruption (a typhoon, a port strike, a geopolitical event) knocks out both simultaneously. True resilience comes from geographic diversification: maintaining at least one domestically produced or nearshore-sourced option for critical categories, even if that supplier handles only 20–30% of volume under normal conditions. This "swing capacity" model requires deliberate contract structuring to keep the secondary supplier commercially viable; a supplier receiving 15% of your volume on a spot basis during normal times cannot realistically scale to 100% in a crisis unless the contract guarantees minimum off-take or a capacity-reservation fee.

Common mistakes

The most common error IDNs make when reshoring is treating it as a binary switch rather than a portfolio adjustment. A large health system that moved the entirety of its PPE spend to a single domestic manufacturer in 2021 — in response to legitimate pandemic-driven risk aversion — found itself paying unit prices 60–80% above pre-pandemic offshore costs with no competitive backstop. When offshore pricing normalized by mid-2022, the system was locked into multi-year contracts with no pricing benchmarks written in. The lesson is that sourcing diversification and cost discipline are not opposites; they require simultaneous management.

A second mistake is neglecting supplier quality infrastructure at domestic facilities. The assumption that "made in America" equals rigorous quality control is not reliable. FDA warning letters and Form 483 observations have been issued to U.S.-based device manufacturers at rates comparable to some regulated offshore regions. Before awarding volume to a domestic supplier based primarily on geography, IDNs should verify ISO 13485:2016 certification scope, review the supplier's most recent FDA inspection classification, and request a summary of open CAPA items — the same due diligence applied offshore.

Third, many IDNs underestimate the lead time required to stand up an alternative domestic source. Qualifying a new medical device supplier under a GPO contract can take 12–18 months when 510(k) verification, quality audits, formulary approval, and value analysis committee review are all accounted for. Health systems that waited until a shortage materialized before initiating qualification had no realistic ability to onboard a domestic alternative in time. The mitigation is pre-qualifying backup sources during stable periods, even if they receive zero purchase orders for years.

Finally, supply-chain leaders sometimes conflate "nearshoring" to Mexico with domestic manufacturing for regulatory purposes. A device assembled in Monterrey is still an imported product under FDA jurisdiction, still subject to tariff classifications, and still requires the same import documentation as a Shenzhen-origin product. The advantage of Mexico is logistics speed (overland transit of 3–7 days versus 4–6 weeks by sea from Asia) and cultural/time-zone alignment for supplier management — not a different regulatory treatment.

A practical workflow

1. Tier your entire device category portfolio by criticality. For each mission-critical category, document current geographic concentration at both the finished-goods and Tier 2 component levels — because a domestically assembled device with a single-source offshore PCB board is not actually onshored.

2. Run a total landed cost model, not a unit-price comparison. Include freight, tariffs, carrying cost of required safety stock, and a probabilistic estimate of stockout cost based on your historical disruption frequency.

3. Verify regulatory status before you commit volume. Confirm 510(k) clearance is tied to the specific manufacturing site you intend to source from, and ask the supplier directly whether any manufacturing changes are pending that could trigger a new submission.

4. Structure contracts to keep swing suppliers viable. If a domestic or nearshore supplier is intended as a backup, build in a minimum annual volume commitment or a capacity-reservation fee so they can sustain operations outside of crisis periods.

5. Pre-qualify at least one geographically distinct alternative for each Tier 1 critical category. Complete all GPO, value analysis, and quality documentation before you need the supplier — not during the shortage.

6. Schedule an annual supply-chain concentration review. Set a threshold (for example, no single country of origin exceeding 70% of volume for any mission-critical category) and treat a breach of that threshold as a procurement action item, not a passive risk note.

Sources

• GAO-21-108: COVID-19: Medical Supply Chain Initial Observations on the Defense Production Act and Other Federal Efforts
• FDA: Quality Management System Regulation (QMSR) — 21 CFR Part 820 Final Rule
• ECRI: Supply Chain Resource Center — Device Shortage Guidance
• Executive Order 13944 on Combating Race to the Bottom: Essential Medicines, Medical Countermeasures, and Critical Inputs